Table 2 Prevalence of seronegative results

Crespo JF, et al. (2002) [16]

Among 336 renal transplant candidates, 33 (9.8%) were seronegative.

Before contraction of primary varicella

–

Level 2

Geel AL, et al. (2006) [17]

Among 854 transplant recipients,

2.1% were seronegative.

Among 286 patients on the wait list, 3.2% patients were seronegative

Before contraction of primary varicella

-Low prevalence of seronegativity.

-At risk of severe complications after contact with chickenpox.

Level 2

Rodríguez-Moreno A, et al. (2006) [13]

Among the four patients that developed primary varicella infection, all were tested negative for VZV IgG.

Presentation/onset of primary varicella

-Varicella infection among renal allograft recipients is unusual but carries a high morbidity and mortality.

Level 3

Kaul A, et al. (2012) [9]

Among 23 renal allograft patients that developed varicella infection, all was tested negative for VZV IgG.

Presentation/onset of primary varicella

–

Level 3

Talebi-Taher M, et al. (2013) [18]

Among 187 patients on haemodialysis, 2.1% were seronegative.

Before contraction of primary varicella

-No correlation between patient’s self-reported history of VZV infection and seroprevalence status (p = 0.6).

-Serologic screening for VZV for transplant candidates is essential.

-Consider this population as a target group for future national immunisation program.

Level 2

Abad CL, et al. (2016) [14]

Among 54 cases of varicella in transplant recipients, baseline serology available in 32 patients,

19 (59.4%) were seronegative.

Presentation/onset of primary varicella

Baseline serologies before transplantation remains useful as markers for prior exposure and latent infection.

It also guides VZV vaccination.

Level 3

Ong CY, et al. (2018) [15]

Presentation/onset of primary varicella

-Immunity to varicella should be screened among ESRD patients.

-Seronegative patients to be considered for varicella vaccination.

Level 3